Why AESIs matter more than ever in Oncology
- Apr 27
- 3 min read
Updated: May 2
If you read a trial paper in oncology, you'll notice a new section: Adverse Events of Special Interest (AESIs).
This isn't regulatory jargon. It's a real shift in how clinicians think about risk, monitoring and treatment selection in the era of immunotherapy, bispecifics and antibody-drug conjugates (ADCs).
What used to be a broad catalog of side effects has evolved into something more focused: a shortlist of toxicities that you actively anticipate, track and act on early.
From "all AEs" to the ones that actually change decisions
Not all adverse events carry equal weight in practice. AESIs stand out because they are:
Mechanistically predictable
Clinically meaningful (even if rare)
Actionable if detected early
In trials, AESIs are now important enough to get their own dedicated analysis and discussion section, separate from the general safety data. That tells you how central they've become to interpreting a drug's real-world usability.
Mechanisms drive AESIs
Across modern oncology therapies, AESIs tend to cluster by drug class:
Immune checkpoint inhibitors
Examples: pembrolizumab, nivolumab
Immune-related adverse events (irAEs):
Pneumonitis
Colitis
Hepatitis
Endocrinopathies
The immune system is disinhibited → autoimmune-like toxicity across organs
Bispecific antibodies
Examples: blinatumomab, teclistamab
Cytokine release syndrome (CRS)
Neurotoxicity (ICANS-like)
Infections
Cytopenias
Continuous T-cell engagement → controlled but persistent immune activation
Antibody-drug conjugates (ADCs)
Examples: trastuzumab deruxtecan, brentuximab vedotin
Interstitial lung disease (ILD)/pneumonitis
Ocular toxicity
Peripheral neuropathy
Myelosuppression
Targeted delivery + cytotoxic payload → organ-specific toxicity patterns
This is where AESIs have become especially critical.
The ADC shift: why AESIs are front and center
As ADCs expand across tumor types, clinicians are increasingly making decisions based on AESI risk, not just efficacy.
A key example is interstitial lung disease (ILD):
ILD is a class-associated AESI for several ADCs
It can be serious or fatal if not recognized early
Prior history of ILD, especially above certain severity thresholds, can exclude patients from receiving these therapies
This is a major shift: a single AESI can determine whether a patient is eligible for a drug.
Ocular toxicity is another emerging class-wide AESI in ADCs, reinforcing that these are not isolated side effects, but predictable patterns tied to the modality itself.
AESIs are shaping how drugs are developed
AESIs don't just influence monitoring, they're now shaping clinical trial design.
In fact:
Trials have explored dose reductions specifically to lower AESI rates
For some ADCs, reducing ILD incidence has been a central development goal
Safety optimization is no longer secondary, it's part of the core value proposition of the drug
This reflects a deeper truth: in oncology today, managing toxicity is inseparable from delivering efficacy.
What this means for clinicians
AESIs aren't just academic. They directly affect day-to-day care:
1. Patient selection
Prior conditions (e.g., ILD) may rule out certain therapies
Comorbidities must be evaluated through the lens of AESI risk
2. Monitoring strategy
AESIs require proactive surveillance, not passive observation
Example: early imaging or symptom checks for pneumonitis
3. Early intervention
Many AESIs are manageable if caught early
Delayed recognition can lead to treatment discontinuation or worse outcomes
4. Treatment choice within a class
When multiple options exist, differences in AESI profiles can drive decisions
It’s no longer just "does it work?" but "how safely can I give it to this patient?"
Bottom line
AESIs represent a shift from reactive toxicity management to anticipatory, mechanism-based care. They matter because they:
Predict the most clinically meaningful risks
Influence who gets treated, and with which therapy
Shape drug development and dosing strategies
Require heightened clinical vigilance
As newer modalities like ADCs and bispecifics expand, AESIs are becoming one of the most important tools clinicians have for delivering safer, more personalized cancer care.